Found: 12
Select item for more details and to access through your institution.
Determinants of patient and physician treatment satisfaction in moderate-to-severe psoriasis: a multinational survey of psoriasis patients.
- Published in:
- Dermatology Online Journal, 2021, v. 27, n. 10, p. 1, doi. 10.5070/D3271055618
- By:
- Publication type:
- Article
Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab.
- Published in:
- Biologics: Targets & Therapy, 2018, v. 12, p. 127, doi. 10.2147/BTT.S172337
- By:
- Publication type:
- Article
A descriptive analysis of real-world treatment patterns of innovator (Remicade<sup>®</sup>) and biosimilar infliximab in an infliximab-naïve Turkish population.
- Published in:
- Biologics: Targets & Therapy, 2018, v. 12, p. 97, doi. 10.2147/BTT.S172241
- By:
- Publication type:
- Article
Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
- Published in:
- Dermatology (10188665), 2022, v. 238, n. 3, p. 438, doi. 10.1159/000519176
- By:
- Publication type:
- Article
Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 2, p. 629, doi. 10.1007/s13555-022-00879-8
- By:
- Publication type:
- Article
Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 2, p. 487, doi. 10.1007/s13555-022-00865-0
- By:
- Publication type:
- Article
Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 4, p. 971, doi. 10.1007/s13555-022-00707-z
- By:
- Publication type:
- Article
Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population—Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 3, p. 741, doi. 10.1007/s13555-022-00691-4
- By:
- Publication type:
- Article
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 97, doi. 10.1007/s13555-021-00637-2
- By:
- Publication type:
- Article
Persistence, Dosing, and Other Treatment Patterns Among Crohn's Disease Patients Initiating Biologics in United States.
- Published in:
- Crohn's & Colitis 360, 2021, v. 3, n. 4, p. 1, doi. 10.1093/crocol/otab076
- By:
- Publication type:
- Article
The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 5, p. 2493, doi. 10.1007/s12325-023-02467-4
- By:
- Publication type:
- Article
Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers.
- Published in:
- 2017
- By:
- Publication type:
- journal article